8-K: Silexion Reports Positive Preclinical Data for Pancreatic Cancer Drug

Silexion Therapeutics announced positive preclinical data for SIL204, demonstrating its reach and activity in major pancreatic cancer metastatic sites following systemic administration.

Summary

• Silexion Therapeutics Corp. announced positive preclinical data for SIL204, an RNA interference (RNAi) therapy for KRAS-driven cancers.
• Subcutaneously administered SIL204 successfully distributed to all major metastatic sites of pancreatic cancer, including the liver, peritoneum, and lung, in a mouse model.
• The study observed measurable reductions in tumor burden across multiple sites, with statistically significant reductions (p<0.01) in the peritoneum (mesentery), lung, and intestine at day 7.
• The data validates the systemic component of Silexion's dual-route administration strategy, which aims to target both primary tumors and disseminated metastatic disease.
• The company remains on track to initiate Phase 2/3 clinical trials in the first half of 2026, following planned regulatory submissions in Q4 2025 and Q1 2026.

Sentiment

Score: 8

Explanation: The preclinical data for SIL204 is highly positive, demonstrating successful drug distribution and anti-tumor activity in metastatic pancreatic cancer, a disease with significant unmet needs. This validates a key component of the company's treatment strategy and provides a clear path towards Phase 2/3 clinical trials, indicating strong progress in its drug development pipeline.

Positives

• SIL204 successfully distributed to all major metastatic sites (liver, peritoneum, lung) following a single subcutaneous injection at a clinically relevant dose (5mg/mouse).
• Measurable reductions in tumor burden were observed across multiple sites, with statistically significant reductions (p<0.01) in the peritoneum (mesentery), lung, and intestine.
• The data provides further validation for the systemic component of a dual-route administration strategy, crucial for addressing metastatic pancreatic cancer which accounts for over 80% of mortality.
• The use of human equivalent dosing in preclinical studies provides important validation for the transition to human clinical trials.
• Silexion remains on track for Phase 2/3 trial initiation in H1 2026, with regulatory submissions planned for Q4 2025 and Q1 2026.

Risks

• Ability to successfully complete preclinical studies and initiate clinical trials.
• Impact of the regulatory environment and compliance complexities.
• Future capital requirements and ability to obtain additional capital.
• Ability to maintain Nasdaq listing.
• Other risks and uncertainties set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2024.

Future Outlook

Silexion Therapeutics plans to conduct expanded tissue culture studies to further characterize SIL204's pan-KRAS potential, with results expected in the near future. The company is on track for regulatory submissions in Q4 2025 and Q1 2026, leading to the initiation of Phase 2/3 clinical trials in the first half of 2026 for its dual-route administration approach.

Management Comments

• "These findings provide additional validation for a critical component of our dual-route administration strategy the ability of subcutaneously delivered SIL204 to reach metastatic sites throughout the body." Mitchell Shirvan, Ph.D., Chief Scientific Officer.
• "Demonstrating drug distribution to the liver, peritoneum, and lung, which represent the primary sites of metastatic pancreatic cancer spread, supports our approach of combining intratumoral delivery for primary tumors with systemic administration for disseminated disease." Mitchell Shirvan, Ph.D., Chief Scientific Officer.
• "This data addresses a fundamental challenge in pancreatic cancer treatment reaching micrometastases that have spread beyond the primary tumor." Ilan Hadar, Chairman and CEO.
• "Combined with our previously reported intratumoral efficacy data, we now have evidence supporting both components of our treatment approach designed to comprehensively address this aggressive disease." Ilan Hadar, Chairman and CEO.

Industry Context

Pancreatic cancer is a highly aggressive disease where over 80% of mortality is attributed to metastatic disease, and more than 40% of initially resectable patients experience recurrence within 12 months, predominantly as distant metastases. Silexion's RNAi therapy, SIL204, targets KRAS-driven cancers, which are considered the most common oncogenic gene driver in human cancers, addressing a significant unmet medical need in oncology.

Stakeholder Impact

• Shareholders: Positive preclinical data and a clear development timeline could lead to increased investor confidence and potential share price appreciation.
• Patients: The successful preclinical results offer hope for a new, more effective treatment option for highly aggressive and often fatal metastatic pancreatic cancer.
• Medical Community: The data contributes to the understanding and development of RNAi therapies for KRAS-driven cancers, potentially influencing future research and treatment paradigms.

Next Steps

• Conduct expanded tissue culture studies across multiple cancer types and KRAS mutations to characterize SIL204's pan-KRAS potential.
• Plan regulatory submissions for SIL204 in Q4 2025 and Q1 2026.
• Initiate Phase 2/3 clinical trials evaluating the dual-route administration approach in H1 2026.

Key Dates

Recommendation

The announcement of positive preclinical data for SIL204, demonstrating successful systemic distribution and anti-tumor activity in major metastatic sites for pancreatic cancer, represents a significant de-risking event for Silexion Therapeutics. Pancreatic cancer is an area of high unmet medical need, and validating the systemic component of their dual-route strategy is a crucial step. The clear timeline for regulatory submissions in Q4 2025/Q1 2026 and Phase 2/3 trial initiation in H1 2026 provides a strong catalyst path. This progress, combined with the potential of RNAi therapies for KRAS-driven cancers, positions the company favorably for future growth and could lead to substantial value creation for investors.

Keywords

Silexion Therapeutics, SIL204, Pancreatic Cancer, Metastasis, RNAi Therapy, KRAS-driven Cancers, Preclinical Data, Oncology, Biotechnology, Clinical Trials, Drug Development